Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Private Plan Outlook Alberta Blue Cross's 2026 drug pipeline report identifies GLP-1 therapies as a major cost driver, stating that while a semaglutide generic is expected in mid-2026, overall GLP-1 therapy plan spend is unlikely to decline in future years due to growing use and continued expansion of GLP-1 therapies [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php]
Patients on GLP-1 medications are at higher risk of muscle loss if protein intake is too low
Ipamorelin $69.00 These products are sold exclusively for laboratory research use only
BMC Evol
Frequently Asked Questions
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice
US$ 24.23
US$ 28.75
US$ 20.09
US$ 20.58
US$ 29.49
US$ 25.14
US$ 21.31
